宜明昂科生物医药技术（上海）股份有限公司（股票名称：宜明昂科-B，股票代码：01541）于2026年7月6日发布翌日报表公告，披露公司于当日回购普通股H股共计10.84万股，占前一次披露时已发行股本（除库存股外）约0.0259%。本次回购价格区间为每股3.73港元至3.85港元，合计涉资409,034港元，折合约40.90万港元。
本次回购完成后，公司已发行股本（不包括库存股）为418,901,705股，库存股数增至1,575,600股，总股本维持在420,477,305股。该回购基于公司于2026年5月28日通过的购回授权，授权可回购股份总数为43,150,769股，截至目前已于交易所回购1,575,600股，占授权通过时公司已发行股本的约0.365%。
公司在公告中确认其已遵守香港联合交易所有限公司证券上市规则及其他相关法律规例。本公告由公司执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.